Consultant ophthalmologist Miss Elizabeth Hawkes explores the causes and treatment approaches for immediate dermal filler-related blindness
Dr Ahmed El Houssieny offers guidance on using botulinum toxin A to address some key aesthetic nasal concerns
Dr Ahmed El Houssieny discusses the evidence for hyperbaric oxygen therapy in the management of vascular compromise and when the treatment may be used in practice
Dr Ahmed El Houssieny reviews the evidence for aspiration when using dermal fillers and suggests ways to minimise risk of vascular compromise
Mr Dalvi Humzah and nurse prescriber Anna Baker provide an update on forehead anatomy and review the current literature to assist with clinical practice
A study from global pharmaceutical company Galderma has indicated that 95% of patients treated with Azzalure abobotulinum toxin A achieved high levels of satisfaction with two treatments per year.
Aesthetic product manufacturer BioScience GmbH has launched Hyaprof, a new injectable line which combines monodensified and polydensified dermal fillers.